Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open deep in red
Thu, 22 Sep 09:30 am

Asian stock markets have opened the day with significant losses. Stock markets in Indonesia (down 4.8%), Hong Kong (down 4.2%), South Korea (down 3.5%) and Taiwan (down 3%) are leading the pack of losers. The Indian stock market have opened the day on a weak note as well. Metals , realty and banking stocks are leading the losses.

The BSE-Sensex is trading lower by around 252 points (1.5%), the NSE-Nifty is down by around 81 points (1.6%). The midcap and smallcap stocks are in the negative as well with both the BSE Mid Cap and BSE Small Cap indices down by 1% and 0.8% respectively. The rupee is trading at 48.75 to the US dollar.

Investment & finance stocks have opened the day on a weak note with Infrastructure Development Finance Company (IDFC), Industrial Finance Corporation of India (IFCI), Power Finance Corporation (PFC) and Reliance Capital facing significant selling pressure. Reliance Capital, the financial services arm of Anil Dhirubhai Ambani Group is planning to sell 26% stake in its subsidiary Reliance General Insurance Company. The due diligence process for the same has already commenced and is expected to complete by the end of financial year 2011-12. In March 2011, Japanese major Nippon Life Insurance Co entered into a definitive agreement with Reliance Capital to acquire a 26% stake in the latter's life insurance arm Reliance Life for Rs 30.6 bn. So far, this has been the largest foreign direct investment in the Indian insurance sector. In early September 2011, Nippon Life signed a pact with Reliance Capital to explore further collaboration including a strategic partnership, across all financial businesses promoted by the latter.

Pharma Stocks have opened the day in the red with Aurobindo Pharma, Biocon, Piramal Healthcare and Sun Pharma leading the losses. The Chairman and Managing Director of Indian biotechnology major Biocon has said that the company aims to achieve revenues of US$ 1 bn (approximately Rs 48.6 bn). By doing this it plans to enter the league of the top ten global biotechnology companies in the world. To achieve this growth, the company's main focus will be on chronic diseases such as diabetes, cancer and auto immune diseases. The company is also planning to list its contract research and manufacturing services arm Syngene in the next 18 months.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open deep in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.